Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.

被引：0
|
作者：
Cho, Jangho
Lim, Jae Yun
Cho, Jae Yong
机构：
[1] Gangnam Severance Hosp, Dept Med Oncol, Seoul, South Korea
[2] Gangnam Severance Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
    Lim, Jae Yun
    Cho, Jang Ho
    Lee, Se Joon
    Lee, Dong Ki
    Yoon, Dong Sup
    Cho, Jae Yong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 266 - 273
  • [2] Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer
    Khatri, P.
    Kumari, P.
    Beniwal, S.
    Samdariya, S.
    ANNALS OF ONCOLOGY, 2016, 27 : 92 - 92
  • [3] A PILOT TRIAL OF GEMCITABINE IN COMBINATION WITH CAPECITABINE OR ERLOTINIB COMPARED TO GEMCITABINE ALONE IN PATIENTS WITH ADVANCED PANCREATIC CANCER
    Cho, J. Y.
    Lim, J. Y.
    Lee, S. J.
    Lee, D. K.
    Park, J. S.
    Yoon, D. S.
    Min, Y. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 240 - 240
  • [4] Comparison of the efficacy of gemcitabine with capecitabine and gemcitabine with erlotinib combination chemotherapy in recurrent or advanced pancreatic cancer as first-line treatment: Single-center experience
    Chun, S.
    Lee, M.
    Jeon, E.
    An, H.
    Hong, T.
    You, Y.
    Kim, D.
    Lee, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [5] A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Kim, Ho Gak
    Noh, Myung Hwan
    Lee, Sang Hyub
    Kim, Yong-Tae
    Kim, Hyo Jung
    Kim, Chang Duck
    Lee, Dong Ki
    Cho, Kwang Bum
    Cho, Chang Min
    Moon, Jong Ho
    Kim, Dong Uk
    Kang, Dae Hwan
    Cheon, Young Koog
    Choi, Ho Soon
    Kim, Tae Hyeon
    Kim, Jae Kwang
    Moon, Jieun
    Shin, Hye Jung
    Song, Si Young
    MEDICINE, 2017, 96 (01)
  • [6] Erlotinib/gemcitabine improves survival in first-line pancreatic cancer patients
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (11): : 1383 - 1383
  • [7] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vaccaro, Vanja
    Bria, Emilio
    Sperduti, Isabella
    Gelibter, Alain
    Moscetti, Luca
    Mansueto, Giovanni
    Ruggeri, Enzo Maria
    Gamucci, Teresa
    Cognetti, Francesco
    Milella, Michele
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (28) : 4511 - 4519
  • [8] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vanja Vaccaro
    Emilio Bria
    Isabella Sperduti
    Alain Gelibter
    Luca Moscetti
    Giovanni Mansueto
    Enzo Maria Ruggeri
    Teresa Gamucci
    Francesco Cognetti
    Michele Milella
    World Journal of Gastroenterology, 2013, (28) : 4511 - 4519
  • [9] Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
    Cohen, D. J.
    Leichman, L. P.
    Love, E.
    Ryan, T.
    Leichman, C. G.
    Newman, E.
    Levinson, B.
    Hochster, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [10] First-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: A multivariate matched pair analysis.
    Stuebs, P.
    Habermann, P.
    Zierau, K.
    Schuette, K.
    Fahlke, J.
    Ridwelski, K.
    Kettner, E.
    Lippert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345